Form 4: Corcept CEO Sells $2.7M in Stock via 10b5-1 Plan

Corcept Therapeutics CEO Joseph K. Belanoff sold 39,000 shares of common stock for approximately $2.7 million through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Inc. (CORT), executed sales of common stock.
• A total of 39,000 shares were sold on August 1, 2025, across three separate transactions.
• The sales were conducted under a Rule 10b5-1 trading plan adopted by Mr. Belanoff on November 26, 2024.
• The shares were sold at weighted average prices of $67.8063, $68.8689, and $69.6483 per share.
• The total approximate value of the shares sold is $2,741,400.
• Following these transactions, Mr. Belanoff's indirect beneficial ownership stands at 2,861,370 shares, held through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, the execution under a pre-arranged Rule 10b5-1 plan mitigates concerns that the sale is based on new, adverse information, making it a routine liquidity event.

Positives

• The stock sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidity event rather than a reaction to new, non-public information.

Negatives

• Insider selling, even when pre-planned, reduces the direct alignment of management's personal financial interests with those of shareholders.

Risks

• No specific risks are detailed, but general market perception of insider selling, even under a 10b5-1 plan, could lead to minor negative sentiment if not fully understood by investors.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

Insider stock sales, particularly those executed under Rule 10b5-1 plans, are a common occurrence in the public markets. These plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information. Such transactions are generally viewed as routine liquidity management rather than a signal of management's view on the company's future performance.

Related Party Transactions

• The shares sold and remaining beneficial ownership are held indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, a related party.

Stakeholder Impact

• Shareholders: Minimal direct impact, as the sale was pre-planned and does not signal new company developments. Transparency of insider transactions is maintained.
• Employees, Customers, Suppliers, Creditors: No direct impact from this transaction.

Key Dates

Recommendation

The stock sale by the CEO was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to new, adverse company developments. While insider selling can sometimes be a negative signal, the existence of a 10b5-1 plan mitigates this concern, making it a neutral event for investment decisions. Investors should focus on the company's fundamental performance and future prospects rather than this routine transaction.

Keywords

Corcept Therapeutics, CORT, Joseph K. Belanoff, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, CEO, Director